Verrica Pharmaceuticals Inc. (VRCA): Price and Financial Metrics
VRCA Price/Volume Stats
| Current price | $3.94 | 52-week high | $8.69 |
| Prev. close | $3.91 | 52-week low | $2.02 |
| Day low | $3.90 | Volume | 177,089 |
| Day high | $4.14 | Avg. volume | 265,052 |
| 50-day MA | $4.87 | Dividend yield | N/A |
| 200-day MA | $5.53 | Market Cap | 165.74M |
VRCA Stock Price Chart Interactive Chart >
VRCA POWR Grades
- VRCA scores best on the Quality dimension, with a Quality rank ahead of 53.99% of US stocks.
- VRCA's strongest trending metric is Sentiment; it's been moving down over the last 177 days.
- VRCA's current lowest rank is in the Momentum metric (where it is better than 3.78% of US stocks).
VRCA Stock Summary
- With a price/sales ratio of 18.52, VERRICA PHARMACEUTICALS INC has a higher such ratio than 94.33% of stocks in our set.
- With a year-over-year growth in debt of -96.86%, VERRICA PHARMACEUTICALS INC's debt growth rate surpasses just 1.03% of about US stocks.
- As for revenue growth, note that VRCA's revenue has grown 1,234.26% over the past 12 months; that beats the revenue growth of 99.28% of US companies in our set.
- Stocks that are quantitatively similar to VRCA, based on their financial statements, market capitalization, and price volatility, are CERS, TARS, ASTC, ORGN, and FOLD.
- VRCA's SEC filings can be seen here. And to visit VERRICA PHARMACEUTICALS INC's official web site, go to www.verrica.com.
VRCA Valuation Summary
- VRCA's price/earnings ratio is -6.8; this is 125.47% lower than that of the median Healthcare stock.
- VRCA's price/sales ratio has moved NA NA over the prior 64 months.
Below are key valuation metrics over time for VRCA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VRCA | 2023-09-22 | 18.5 | 2.9 | -6.8 | -4.5 |
| VRCA | 2023-09-21 | 18.3 | 2.8 | -6.7 | -4.5 |
| VRCA | 2023-09-20 | 19.6 | 3.0 | -7.2 | -4.9 |
| VRCA | 2023-09-19 | 19.6 | 3.1 | -7.2 | -4.9 |
| VRCA | 2023-09-18 | 19.2 | 3.0 | -7.0 | -4.8 |
| VRCA | 2023-09-15 | 19.8 | 3.1 | -7.3 | -5.0 |
VRCA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VRCA has a Quality Grade of D, ranking ahead of 15.27% of graded US stocks.
- VRCA's asset turnover comes in at 0.133 -- ranking 235th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows VRCA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.133 | 1 | -0.503 |
| 2021-03-31 | 0.137 | 1 | -0.549 |
| 2020-12-31 | 0.000 | NA | -0.697 |
| 2020-09-30 | 0.000 | NA | -0.639 |
| 2020-06-30 | 0.000 | NA | -0.574 |
| 2020-03-31 | 0.000 | NA | -0.496 |
VRCA Price Target
For more insight on analysts targets of VRCA, see our VRCA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $19.86 | Average Broker Recommendation | 1.42 (Moderate Buy) |
Verrica Pharmaceuticals Inc. (VRCA) Company Bio
Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is based in West Chester, Pennsylvania.
Latest VRCA News From Around the Web
Below are the latest news stories about VERRICA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VRCA as an investment opportunity.
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment ConferenceWEST CHESTER, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that that Ted White, Verrica President and CEO, will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 5:00 pm ET. The Company will also be participating in one-on-one |
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF EnterprisesYCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children FFF Enterprises is Verrica’s exclusive distribution partner for YCANTH™ WEST CHESTER, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interve |
Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum ContagiosumVerrica’s product YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children YCANTH™ is expected to be available for commercial use by licensed healthcare providers by September 2023 WEST CHESTER, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing med |
Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy MeetingPresentation highlights the antitumor response of VP-315 for the non-surgical treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for non-surgical treatment options WEST CHESTER, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developi |
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – – YCANTH™ launch expected by September 2023 – – Expanding Part 2 enrollment of ongoing Phase 2 trial of VP-315 in basal cell carcinoma to accelerate clinical development – – Secured $125 million debt facility to support launch of YCANTH™ – Cash runway extended into the first quarter of 2025 – WEST CHE |
VRCA Price Returns
| 1-mo | -12.25% |
| 3-mo | -31.48% |
| 6-mo | -40.66% |
| 1-year | 34.47% |
| 3-year | -51.66% |
| 5-year | -75.86% |
| YTD | 43.27% |
| 2022 | -69.98% |
| 2021 | -20.42% |
| 2020 | -27.56% |
| 2019 | 94.97% |
| 2018 | N/A |
Loading social stream, please wait...